An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (ODYSSEY KIDS)
An 8-Week Open-Label, Sequential, Repeated Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia Followed by an Extension Phase
Sponsor: Regeneron Pharmaceuticals
This PHASE2 trial investigates Hypercholesterolaemia and is currently completed. Regeneron Pharmaceuticals leads this study, which shows 21 recorded versions since 2016 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
21 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Oct 2019 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 16 earlier versions
-
Apr 2019 — Oct 2019 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Mar 2019 — Apr 2019 [monthly]
Active Not Recruiting PHASE2
-
Nov 2018 — Mar 2019 [monthly]
Active Not Recruiting PHASE2
-
Oct 2018 — Nov 2018 [monthly]
Active Not Recruiting PHASE2
-
Aug 2018 — Oct 2018 [monthly]
Active Not Recruiting PHASE2
-
Jul 2018 — Aug 2018 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE2
-
Feb 2018 — Jun 2018 [monthly]
Recruiting PHASE2
Status: Active Not Recruiting → Recruiting
-
Oct 2017 — Feb 2018 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2017 — Oct 2017 [monthly]
Recruiting PHASE2
-
Aug 2017 — Sep 2017 [monthly]
Recruiting PHASE2
-
Jun 2017 — Aug 2017 [monthly]
Recruiting PHASE2
-
May 2017 — Jun 2017 [monthly]
Recruiting PHASE2
-
Mar 2017 — May 2017 [monthly]
Recruiting PHASE2
-
Feb 2017 — Mar 2017 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Sep 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Regeneron Pharmaceuticals
- Sanofi
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
A Coruña, Spain , Amsterdam, Netherlands , Brno, Czechia , Bron, France , Charlotte, United States , Cincinnati, United States , Kemerovo, Russia , Madrid, Spain , Oslo, Norway , Parow, South Africa and 6 more locations